Abstract
Autism spectrum disorders (ASD) are a cluster of developmental disorders, whose core symptoms can be attributed to abnormal development of the large-scale neural networks required for social communication. The impaired delivery of afferent signals has been proposed to be associated with impaired social interaction in ASD. Arachidonic acid (ARA) and docosahexaenoic acid (DHA) play key roles in the maturation of brain network. In particular, ARA promotes signal transduction related to neural function. It is therefore possible that supplementation with larger ARA doses added to DHA may mitigate the impaired social interaction observed in ASD. There have been no double-blind randomized placebo-controlled studies of the effect of large doses of ARA, added to DHA, on the impaired social interactions observed in ASD. This article presents the results of a 16-week double-blind randomized placebo-controlled trial in which high-dose ARA was added to DHA supplementation in individuals with ASD (n=13). The primary outcomes were measured using the Social Responsiveness Scale (SRS) and the secondary outcome measure was Autism Diagnostic Interview-revised (ADI-R) social and communication domains. Supplementation of larger doses of ARA added to DHA significantly improved SRS-measured communication and ADI-measured social communication. At the end of trial, the increase in plasma ARA levels from the baseline observed in the ARA treatment group was significantly higher compared to placebo group.
Keywords: Autism spectrum disorders, impaired social interaction, arachidonic acid, dietary supplementation, clinical trial, signal transduction
Current Psychopharmacology
Title:Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Volume: 2
Author(s): K. Yui, K. Koshiba and S. Nakamura
Affiliation:
Keywords: Autism spectrum disorders, impaired social interaction, arachidonic acid, dietary supplementation, clinical trial, signal transduction
Abstract: Autism spectrum disorders (ASD) are a cluster of developmental disorders, whose core symptoms can be attributed to abnormal development of the large-scale neural networks required for social communication. The impaired delivery of afferent signals has been proposed to be associated with impaired social interaction in ASD. Arachidonic acid (ARA) and docosahexaenoic acid (DHA) play key roles in the maturation of brain network. In particular, ARA promotes signal transduction related to neural function. It is therefore possible that supplementation with larger ARA doses added to DHA may mitigate the impaired social interaction observed in ASD. There have been no double-blind randomized placebo-controlled studies of the effect of large doses of ARA, added to DHA, on the impaired social interactions observed in ASD. This article presents the results of a 16-week double-blind randomized placebo-controlled trial in which high-dose ARA was added to DHA supplementation in individuals with ASD (n=13). The primary outcomes were measured using the Social Responsiveness Scale (SRS) and the secondary outcome measure was Autism Diagnostic Interview-revised (ADI-R) social and communication domains. Supplementation of larger doses of ARA added to DHA significantly improved SRS-measured communication and ADI-measured social communication. At the end of trial, the increase in plasma ARA levels from the baseline observed in the ARA treatment group was significantly higher compared to placebo group.
Export Options
About this article
Cite this article as:
Yui K., Koshiba K. and Nakamura S., Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010084
DOI https://dx.doi.org/10.2174/2211556011302010084 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Olfactory Loss and Dysfunction in Ciliopathies: Molecular Mechanisms and Potential Therapies
Current Medicinal Chemistry Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson’s Disease
Current Drug Targets Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology An Overview of Pharmacogenetics in Psychotropic Drugs
Current Psychiatry Reviews A Review on Emerging Drug Targets in Treatment of Schizophrenia
Current Drug Targets Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Neural Basis of Dental Pulp Stem Cells and its Potential Application in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Transcriptomics of Antipsychotic Drug Function: What have we Learned from Rodent Studies?
Current Psychopharmacology Atypical antipsychotics and inverse agonism at 5-HT<sub>2</sub> receptors
Current Pharmaceutical Design Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
CNS & Neurological Disorders - Drug Targets Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets